- Home
- SKT vs TVTX Comparison
SKT vs TVTX Comparison
Compare SKT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKT | TVTX |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.3B |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SKT | TVTX |
|---|---|---|
| Price | $38.57 | $66.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $37.17 | ★ $40.62 |
| AVG Volume (30 Days) | 789.5K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.37 | $44.76 |
| Revenue Next Year | $3.90 | $35.51 |
| P/E Ratio | $73.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.13 | $17.05 |
| 52 Week High | $42.53 | $66.38 |
Technical Indicators
Market Signals| Indicator | SKT | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 67.15 |
| Support Level | $38.43 | $53.76 |
| Resistance Level | $41.27 | $66.24 |
| Average True Range (ATR) | 0.61 | 2.16 |
| MACD | -0.04 | 0.31 |
| Stochastic Oscillator | 40.00 | 88.06 |
Price Performance
Historical ComparisonAbout SKT Tanger Inc.
Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.